

MOTIV™ TKA CIRCLE DATASET

VALUATION AND FUNDING ANALYSIS

March 2026

TABLE OF CONTENTS

EXECUTIVE SUMMARY	2
CLINICAL AND PSYCHOMETRIC INTEGRITY OF THE OP	2
VALIDATED PATIENT-REPORTED OUTCOME MEASURES	3
GRANULAR SURGICAL AND OPIOID TRACKING VARIABLES.....	3
ECONOMIC VALUATION MODELS AND INDUSTRY BENCHMARKS	4
COMMERCIAL MARKET COMPARISON AND LICENSING STRUCTURES	4
INTERNAL COST-AVOIDANCE ANALYSIS.....	5
THE HIDDEN COSTS OF DELAY.....	6
PER-RECORD MULTIPLE AND MARKET SCALING.....	6
REGULATORY UTILITY AND COMPLIANCE FRAMEWORKS.....	6
EU MDR AND ANNEX XIV REQUIREMENTS	6
FDA GUIDANCE ON REAL-WORLD EVIDENCE	7
DATA INTEGRITY AND THE ALCOA+ STANDARD.....	7
STRATEGIC VALUE OF COMPETITIVE INTELLIGENCE	7
SURGEON-LEVEL TARGETING AND PERFORMANCE BENCHMARKING.....	8
PRICING AND REIMBURSEMENT STRATEGY	8
FUNDING SOURCES: FEDERAL GRANTS AND PUBLIC HEALTH UTILITIES	8
DEPARTMENT OF DEFENSE: PEER REVIEWED ORTHOPAEDIC RESEARCH PROGRAM	9
NATIONAL INSTITUTES OF HEALTH: HEAL AND NIAMS	9
ACCESSING OPIOID SETTLEMENT FUNDS FOR ABATEMENT RESEARCH	9
THE ABATEMENT STRATEGY FRAMEWORK	10
<i>Mapping the Protocol to Approved Uses</i>	10
MODULAR LICENSING AND REVENUE MULTIPLIERS	10
SKU-BASED PRODUCTIZATION.....	11
CONCLUSION	11
REFERENCES	12